Pure Global
NCT03107078

Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial

Using A Novel Classification System in Intravenous Glucocorticoids Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial
Jie Shen·Phase 4·ClinicalTrials.gov·drug
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Thyroid Associated Ophthalmopathy
Drug/Device/Intervention
Glucocorticoids
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jie Shen
Funder
The Third Affiliated Hospital of Southern Medical University
Location
Guangzhou, China
Timeline & enrollment
Phase
Phase 4
Start date
Oct 01, 2016
End date
Oct 01, 2021
Enrollment
200 participants
Primary outcome

Number of patients defined as Response for the Glucocorticoids Treatment based on the 7 parameters of eye assessment,Number of patients defined as Deterioration for the Glucocorticoids Treatment based on the 7 parameters of eye assessment,Number of patients defined as Unchange for the Glucocorticoids Treatment based on the 7 parameters of eye assessment

Summary

For patients with active moderate-to-severe thyroid associated ophthalmopathy (TAO), the
 Intravenous Glucocorticoids (GCs) is the recommended therapy. However, the efficacy of GCs is
 not satisfied. Investigators established a novel classification of TAO for the first time to
 assess more precisely for better personal treatment.

ICD-10 classifications
ThyroiditisDisorders of thyroid glandThyroiditis, unspecifiedOther disorders of thyroidDisorder of thyroid, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03107078
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03107078 through Pure Global AI's free database. This Phase 4 trial is sponsored by Jie Shen and is currently status unknown. The study focuses on Thyroid Associated Ophthalmopathy. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.